SCHEMBL975372

SCHEMBL975372

COC(=O)c1cc(F)cc(NS(=O)(=O)CC2CN(C(c3ccc(F)cc3)c3ccc(F)cc3)C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
MGLL Q99685 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 1/20 0.37
SCN9A Q15858 3/20 0.36
HPGD P15428 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ATM Q13315 1/20 0.36
OPRD1 P41143 3/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SCN7A Q01118 1/20 0.35
SCN5A Q14524 1/20 0.35
HTR1F P30939 1/20 0.35
GRIA2 P42262 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979322 0.94 TCF4 (0.37) KDM4EMGLLKMT2AMEN1LMNA
SCHEMBL977022 0.93 SLC6A9 (0.37) KDM4EKMT2AMEN1LMNASCN9A
SCHEMBL977906 0.91 ACHE (0.42) MGLLKMT2AMEN1LMNASCN9A
SCHEMBL977228 0.89 PPARA (0.41) MGLLSCN9ASCN7ASCN5AHTR1F
SCHEMBL974855 0.86 HPGD (0.38) MGLLKMT2AMEN1LMNASCN9A
SCHEMBL977371 0.86 FABP4 (0.41) MGLLKMT2AMEN1LMNASCN9A
SCHEMBL977039 0.85 NHERF1 (0.40) KMT2AMEN1LMNASCN9AHPGD
SCHEMBL978430 0.85 HPGD (0.38) LMNASCN9AHPGDOPRD1CA1
SCHEMBL975275 0.84 SLC6A9 (0.39) KDM4EKMT2AMEN1LMNAHPGD
SCHEMBL978278 0.84 FABP4 (0.37) LMNASCN9ASCN7ASCN5AGRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI (FR) 2013-09-12 US claimed
EP-2234966-B1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI SA (FR) 2013-09-11 EP claimed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US claimed
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI (FR) 2013-09-12 US disclosed
US-8445478-B2 Azetidine derivatives, their preparation and their application in therapy SANOFI (FR) 2013-05-21 US disclosed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B KDM4E 1074/4885MGLL 4653/4885KMT2A 2003/4885
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B KDM4E 1074/4885MGLL 4653/4885KMT2A 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.